From June 16–18, MediumBank participated in CPHI & PMEC China 2026 in Shanghai, one of the pharmaceutical industry's leading events in Asia. Throughout the exhibition, discussions with biopharmaceutical manufacturers, CDMOs, and technology partners revealed a common priority across global markets: building more resilient and reliable bioprocess supply chains.
Industry Priorities Are Evolving
Conversations throughout the event reflected a broader industry shift: developers are increasingly evaluating suppliers based on their ability to support long-term manufacturing success.
Three themes consistently emerged during discussions with customers:
l Ensuring supply security and manufacturing continuity
l Maintaining batch-to-batch consistency at scale
l Accelerating the transition from process development to commercial production
These priorities highlight the growing importance of reliable manufacturing infrastructure and supply chain resilience in today's biopharmaceutical industry.
Enabling Reliable and Scalable Manufacturing
To support these evolving industry needs, MediumBank showcased its integrated portfolio of cell culture media and manufacturing services for biopharmaceutical and cell therapy applications.
Key solutions on display included MediumBank's CHO cell culture media and cell therapy media platforms, developed to support robust cell growth, process consistency, and scalable manufacturing.
In addition to media products, MediumBank highlighted two manufacturing service platforms:
l Rapid Powder Production (RPP), enabling flexible media customization, pilot-scale production, and commercial-scale supply.
l Efficient Hydration Solutions (EHS), providing standardized and reliable conversion of dry powder media into high-quality liquid media.
To meet these expectations, MediumBank continues to invest in manufacturing capacity, quality systems, and process standardization. Backed by GMP manufacturing facilities in Shanghai and Nanjing, the company provides flexible production capabilities that support customers from early development through commercial manufacturing.
MediumBank is also advancing its AI Media Optimization & Development(AIMD) platform to accelerate media optimization and improve development efficiency, helping customers bring therapies to market faster.
Looking Ahead
We sincerely thank all customers, partners, and industry professionals who visited Booth W9B67 during CPHI & PMEC China 2026.
As demand for biologics and advanced therapies continues to grow worldwide, MediumBank remains committed to delivering reliable products, flexible manufacturing services, and innovative technologies that support customers from process development through commercial manufacturing.
